Log in

NASDAQ:NUVANuVasive Stock Price, Forecast & News

$62.84
-0.82 (-1.29 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$62.09
Now: $62.84
$64.05
50-Day Range
$43.51
MA: $56.40
$62.69
52-Week Range
$28.55
Now: $62.84
$81.91
Volume372,844 shs
Average Volume794,390 shs
Market Capitalization$3.22 billion
P/E Ratio54.64
Dividend YieldN/A
Beta1.44
NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally-disruptive fashion. The company's biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.
Read More
NuVasive logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 billion
Cash Flow$5.51 per share
Book Value$17.29 per share

Profitability

Net Income$65.23 million

Miscellaneous

Employees2,800
Market Cap$3.22 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

How has NuVasive's stock been impacted by COVID-19 (Coronavirus)?

NuVasive's stock was trading at $49.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NUVA shares have increased by 27.2% and is now trading at $62.84. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NuVasive?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NuVasive.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for NuVasive.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) posted its earnings results on Wednesday, May, 6th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.41 by $0.07. The medical device company earned $259.88 million during the quarter, compared to the consensus estimate of $262.32 million. NuVasive had a net margin of 5.30% and a return on equity of 14.42%. The company's quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.53 EPS. View NuVasive's earnings history.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its first quarter 2020 After-Hours earnings guidance on Tuesday, April, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $259-261 million, compared to the consensus revenue estimate of $282 million.

What price target have analysts set for NUVA?

18 equities research analysts have issued 1 year target prices for NuVasive's stock. Their forecasts range from $55.00 to $93.00. On average, they anticipate NuVasive's share price to reach $71.12 in the next twelve months. This suggests a possible upside of 13.2% from the stock's current price. View analysts' price targets for NuVasive.

Has NuVasive been receiving favorable news coverage?

Media stories about NUVA stock have been trending very negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NuVasive earned a coverage optimism score of -3.9 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutNuVasive.

Are investors shorting NuVasive?

NuVasive saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,920,000 shares, an increase of 11.6% from the April 30th total of 4,410,000 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is presently 4.3 days. Currently, 9.7% of the shares of the stock are short sold. View NuVasive's Current Options Chain.

Who are some of NuVasive's key competitors?

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include Incyte (INCY), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Starbucks (SBUX), Medivation (MDVN), Alibaba Group (BABA), Global Sources Ltd. (Bermuda) (GSOL), Netflix (NFLX), Intel (INTC) and Celgene (CELG).

Who are NuVasive's key executives?

NuVasive's management team includes the following people:
  • Mr. J. Christopher Barry, CEO & Director (Age 46)
  • Mr. Matthew W. Link, Pres (Age 44)
  • Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 56)
  • Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 52)
  • Mr. Jereme Sylvain, Chief Accounting Officer (Age 39)

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (1.99%), Lord Abbett & CO. LLC (1.71%), Geode Capital Management LLC (1.49%), Victory Capital Management Inc. (1.43%), Victory Capital Management Inc. (1.43%) and Primecap Management Co. CA (1.33%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock. View institutional ownership trends for NuVasive.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Victory Capital Management Inc., Victory Capital Management Inc., Rice Hall James & Associates LLC, Primecap Management Co. CA, UBS Group AG, Carillon Tower Advisers Inc., and Sector Gamma AS. Company insiders that have sold NuVasive company stock in the last year include Gregory T Lucier, Matthew Link, and Paul Mcclintock. View insider buying and selling activity for NuVasive.

Which institutional investors are buying NuVasive stock?

NUVA stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Loomis Sayles & Co. L P, Ziegler Capital Management LLC, Federated Hermes Inc., Acadian Asset Management LLC, AQR Capital Management LLC, Martingale Asset Management L P, and Symphony Asset Management LLC. View insider buying and selling activity for NuVasive.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $62.84.

How big of a company is NuVasive?

NuVasive has a market capitalization of $3.22 billion and generates $1.17 billion in revenue each year. The medical device company earns $65.23 million in net income (profit) each year or $2.47 on an earnings per share basis. NuVasive employs 2,800 workers across the globe.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.